<DOC>
	<DOCNO>NCT01907685</DOCNO>
	<brief_summary>Primary Objective : To determine dose limit toxicity ( DLT ) , maximum administer dose ( MAD ) maximum tolerate dose ( MTD ) AVE8062 docetaxel combination administer sequentially D1 &amp; D2 respectively every 3 week patient advance solid tumor . Secondary Objectives : - To define overall safety profile combination . - To characterize pharmacokinetic ( PK ) profile AVE8062 docetaxel administer combination . - To evaluate anti-tumor activity combination . - To evaluate potential predictive biomarkers . The study include tumoral pharmacogenomic sub-study conduct subset site . The objective analyse set biological biomarkers order identify potential predictive signature efficacy AVE8062 combination docetaxel .</brief_summary>
	<brief_title>Dose Escalation , Safety Pharmacokinetic Study AVE8062 Combined With Docetaxel Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The duration study patient include 4-week screening phase prior first inclusion study drug , 21-day study treatment cycle , end treatment visit follow-up phase . Each patient treat disease progression , unacceptable toxicity study discontinuation criterion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : Advanced neoplastic disease ( i.e metastatic locally advanced disease ) docetaxelbased regimen therapy indicate breast , nonsmall cell lung prostate cancer . ECOG performance status 0 1 . Exclusion criterion : Concurrent treatment anticancer therapy . Patient locally advance metastatic breast cancer never receive adjuvant chemotherapy . Brain metastases carcinomatous leptomeningitis . Prior intensive chemotherapy autologous stem cell rescue . Patients receive high cumulative dose anthracycline ( i.e doxorubicin &gt; 400mg/m2 epirubicin &gt; 750 mg/m2 ) . Impaired cardiovascular function . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>